A Phase I, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2015
At a glance
- Drugs AZD 5213 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors AstraZeneca
- 12 Jul 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 12 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2010 Planned end date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.